MaxCyte (MXCT)
(Delayed Data from NSDQ)
$4.49 USD
+0.03 (0.67%)
Updated Jul 12, 2024 04:00 PM ET
After-Market: $4.52 +0.03 (0.67%) 7:58 PM ET
1-Strong Buy of 5 1
F Value D Growth F Momentum F VGM
Price, Consensus and EPS Surprise
MXCT 4.49 +0.03(0.67%)
Will MXCT be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for MXCT based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for MXCT
Does MaxCyte (MXCT) Have the Potential to Rally 85% as Wall Street Analysts Expect?
Recent Price Trend in MaxCyte (MXCT) is Your Friend, Here's Why
MXCT: What are Zacks experts saying now?
Zacks Private Portfolio Services
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Tops Revenue Estimates
Qiagen (QGEN) Surpasses Q2 Earnings and Revenue Estimates
MaxCyte, Inc. (MXCT) Reports Q1 Loss, Lags Revenue Estimates
Other News for MXCT
MaxCyte to Report Second Quarter 2024 Financial Results on August 6, 2024
MaxCyte Releases Key Annual Report for 2023
Craig-Hallum Reaffirms Their Buy Rating on MaxCyte (MXCT)
MaxCyte Awards Stock Options and RSUs to Directors
MaxCyte AGM Concludes with Positive Outcomes